Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 11638744
    Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 2, 2023
    Inventors: Shiro Shibayama, Hiroshi Arima, Takuya Simbo
  • Patent number: 11633419
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 25, 2023
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
  • Patent number: 11603569
    Abstract: Immune-modulating genes are provided for prognosis and diagnosis of metastases or reoccurrence of cancer, as well as methods of prognosis, diagnosis, prophylaxis and treatment of cancer metastases.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 14, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventor: Richard Essner
  • Patent number: 11597769
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 7, 2023
    Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical Research
    Inventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu Joy Xie
  • Patent number: 11555197
    Abstract: The invention provides a compositions and methods for controlling phenotypic traits in plants. Genes of interest are placed under the control of a gene switch to allow inducible control or expression of a gene of interest “on-demand” by treatment of the plant with a chemical ligand.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: January 17, 2023
    Assignee: GREENVENUS, LLC
    Inventors: Sekhar Boddupalli, Andrey Boukharov, Rio Stamler, Zhongsen Li, Arianne Tremblay, Stephen Schauer, Shiv B. Tiwari, John Salmeron
  • Patent number: 11518797
    Abstract: Provided herein are compositions, proteins, polynucleotides, expression vectors, host cells, kits, and systems for producing egg white proteins, as well as methods of using the same.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: December 6, 2022
    Assignee: CLARA FOODS CO.
    Inventor: David Anchel
  • Patent number: 11512126
    Abstract: A non-naturally occurring chimeric polypeptide having an activity provided by a TGF-beta family member is disclosed. The chimeric polypeptide of an embodiment comprises two or more domains or fragments from parental TGF-beta proteins operably linked such that the resulting polypeptide is capable of modulating a pathway associated with a TGF-beta family member. In one embodiment, the pathway is a SMAD or DAXX pathway.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: November 29, 2022
    Inventors: Sen Yon Choe, Chi Hoon Ahn, Ho Cheol Kim, Hyeon Jin Kim
  • Patent number: 11505585
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 22, 2022
    Assignees: argenx BV, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 11505589
    Abstract: An antitumor peptide provided according to the present invention includes (1) an S1PR-TM related sequence; and (2) an amino acid sequence functioning as a cell penetrating peptide; wherein the total number of amino acid residues is 100 or less.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: November 22, 2022
    Assignees: TOAGOSEI CO., LTD, National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada
  • Patent number: 11473113
    Abstract: Provided are a cAMP receptor protein variant and coding sequence, a microorganism including the same, and a method of producing a L-amino acid using the same.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: October 18, 2022
    Inventors: Seok Myung Lee, Ki Yong Cheong, Chang Il Seo, Ji Sun Lee
  • Patent number: 11471502
    Abstract: Inhibitors of MAPK3 (ERK1 MAP kinase), in particular polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents, are disclosed. Related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway, are also disclosed. Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: October 18, 2022
    Assignee: University College Cardiff Consultants Ltd
    Inventors: Riccardo Brambilla, Stefania Fasano, Marzia Indrigo, Alessandro Papale
  • Patent number: 11464844
    Abstract: Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: October 11, 2022
    Assignee: Boston Medical Center Corporation
    Inventor: Richard N. Goldstein
  • Patent number: 11460469
    Abstract: The invention relates to biosensors for detecting odorants, especially a biosensor that mimics odorant detection by a mammal, for example, humans, dogs or cats. The field of the invention also related to the standardization of odors for scent, smell and taste using the biosensor of the invention, and the discovery of agonists, antagonists, and mixtures of odorants for creating new odors, masking odors, enhancing odors, and designing odors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 4, 2022
    Assignee: Aromyx Corporation
    Inventors: Chris Hanson, William Harries, Victor Todd Cushman, Ed Costello
  • Patent number: 11459401
    Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 4, 2022
    Assignee: Amgen Inc.
    Inventors: Alona Teran, Qahera Munaim, Nazer Khalaf, Rahul Rajan Kaushik, Christi L. Clogston, Twinkle R. Christian, William J. Callahan
  • Patent number: 11459386
    Abstract: Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: October 4, 2022
    Assignee: Sesen Bio, Inc.
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
  • Patent number: 11452763
    Abstract: Growth hormone receptor antagonists, comprising human growth hormone receptor antagonist G120K, wherein one amino acid of human growth hormone receptor antagonist G120K has been mutated to cysteine or wherein two amino acids of human growth hormone receptor antagonist G120K have been mutated to cysteine, and wherein the one amino acid mutated to cysteine is T142, and wherein the two amino acids mutated to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K mutant. These growth hormone receptor antagonists are useful in treating diseases or conditions, such as cancer and acromegaly, that are responsive to human growth hormone receptor antagonists.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: September 27, 2022
    Inventors: Richard S. Brody, Thomas J. Zupancic, John J. Kopchick, Reetobrata Basu
  • Patent number: 11446238
    Abstract: Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 ?m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 ?m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 20, 2022
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra Navath, Anupa Menjoge
  • Patent number: 11440941
    Abstract: A cancer killer cell in which a therapeutic recombinant protein or recombinant protein which improves cytotoxic activity of the cancer killer cell is loaded. In addition, a pharmaceutical composition including the recombinant protein or a recombinant protein-loaded cancer killer cell is disclosed. Further, disclosed is a method for preparing a recombinant protein-loaded cancer killer cell.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 13, 2022
    Assignee: Gwangju Institute of Science and Technology
    Inventors: Chang-Duk Jun, Bu Nam Jeon, Hey-Ran Kim
  • Patent number: 11414591
    Abstract: This invention relates to compositions and methods of microbial enhanced oil recovery using biochemical-producing microbes. In specific embodiments, the methods of the subject invention comprise applying a bio surfactant-producing bacteria and/or a growth by-product thereof to an oil-producing site. In preferred embodiments, the bacteria is a strain of Bacillus in spore form. In some embodiments, the methods further comprise applying the bacteria with a yeast fermentation product, an alkaline compound, a polymer, a non-biological surfactant, and/or one or more chelating agents. Advantageously, the subject invention can be useful for stimulating the flow of oil from a well, as well as dissolving scale present in an oil-bearing formation.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: August 16, 2022
    Inventors: Sean Farmer, Ken Alibek, Sharmistha Mazumder, Kent Adams, Tyler Dixon, Yajie Chen, Maja Milovanovic
  • Patent number: 11407799
    Abstract: A compound comprising at least two components, a first component being the nLG3 or (h)nLG3 domain from the C-terminus of mouse or human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities. Such compounds are effective treatments for neuromuscular diseases and problems.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 9, 2022
    Inventors: Jan Willem Vrijbloed, Marina Maria Boido, Olena Butenko, Roberta Schellino
  • Patent number: 11390647
    Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 19, 2022
    Assignee: BGI SHENZHEN
    Inventors: Yunxia Tang, Bo Li, Yong Hou, Ying Huang, Cheng Cheng, Shuntao Luo
  • Patent number: 11391737
    Abstract: In some embodiments, a method for aiding prediction of the likelihood of progression from Barrett's esophagus to high grade dysplasia or esophageal adenocarcinoma in a subject, is disclosed. The method can include (a) providing an oesophagal sample from said subject (b) determining if said sample stains abnormally with Aspergillus oryzae lectin; (c) determining if there is a DNA content abnormality in said sample; and (d) determining if there is low grade dysplasia in said sample; wherein if (b) is abnormal and (c) is abnormal and low grade dysplasia is present, then an increased likelihood of progression is determined. The disclosed subject matter also relates to an apparatus, and to different uses of certain materials.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: July 19, 2022
    Inventors: Rebecca Fitzgerald, Elizabeth Bird-Lieberman
  • Patent number: 11382937
    Abstract: Provided is a pharmaceutical composition for the prevention, alleviation, or treatment of inflammatory diseases, metabolic diseases, and cancer, comprising a Streptococcus pyogenes culture broth or a protein isolated from the culture broth as an active ingredient. The inventors of the presently claimed subject matter confirmed that, when administered to inflammatory disease, metabolic disease, and cancer models, a Streptococcus pyogenes culture broth or a protein isolated from the culture broth exhibited anti-inflammatory, anti-obesity, liver function-improving, and anticancer effects, and thus the Streptococcus pyogenes culture broth or the protein isolated from the culture broth according to the presently claimed subject matter can be effectively used to develop a drug, a health functional food, an inhalant, a cosmetic composition, or the like for preventing inflammatory diseases, metabolic diseases, and cancer, or alleviating or treating symptoms thereof.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: July 12, 2022
    Assignee: MD HEALTHCARE INC.
    Inventors: Yoon-Keun Kim, Jae Gyu Kim, Tae Seop Shin
  • Patent number: 11371033
    Abstract: A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having ?2-3-linked N-glycolylneuraminic acid and glycans having ?2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having ?2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having ?2-3-linked N-glycolylneuraminic acid.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 28, 2022
    Assignees: Griffith University, The University of Adelaide
    Inventors: Michael Paul Jennings, Christopher Day, Adrienne Webster Paton, James Cleland Paton
  • Patent number: 11369659
    Abstract: There is provided a composition for improving memory, learning ability, and cognitive ability and a method of enhancing a brain or cognitive function by administering the composition to a subject in need thereof. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least 4 amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability, and the method of enhancing a brain or cognitive function.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: June 28, 2022
    Assignee: Brainon Inc.
    Inventor: Yong Koo Kang
  • Patent number: 11365399
    Abstract: A recombinant protein, including: (a) alpha subunit of an FAD-GDH; and (b) a minimal cytochrome c peptide is provided. Additionally, an electrode coupled to a recombinant protein, the recombinant protein made of: (a) a cofactor of a redox enzyme; (b) a redox enzyme; (c) a linker moiety configured to link any one of: the cofactor or the enzyme to an electron transfer (ET) domain; and (d) an ET domain, is also provided. Methods for: (a) transferring an electron to an electrode, by coupling the recombinant protein an electrode; and (b) quantifying the amount of an analyte e.g., glucose are also provided.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 21, 2022
    Inventors: Lital Alfonta, Raz Zarivach, Jennifer Grushka, Itay Algov
  • Patent number: 11357821
    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 14, 2022
    Inventors: Juergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
  • Patent number: 11352412
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 11345959
    Abstract: Provided is a method for analyzing metagenomic information using a degenerate primer which can be applied for quickly determining the utility value of a massive amount of metagenome samples. In particular, the superfamily-specific degenerate primer of the present invention is used to quickly detect the presence or absence of the genetic information of the target peptides in the metagenome by a simple method, thereby collecting a large amount of useful peptide resource information from various metagenome samples at high speed. Further, the present invention may be used for screening new peptide genes by designing and producing superfamily-specific degenerate primers of new target peptides based on the method of the present invention.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: May 31, 2022
    Inventor: Dong Woo Lee
  • Patent number: 11345733
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 31, 2022
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew Bristol
  • Patent number: 11332539
    Abstract: Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: May 17, 2022
    Assignee: Thomas Jefferson University
    Inventor: Mark L. Tykocinski
  • Patent number: 11332516
    Abstract: Disclosed are methods by which compounds/molecules capable of binding antigens, for example antibody type compounds/molecules, can be purified, extracted and/or selected. The methods may be used to purify, extract or select a specific type (or types) of binding agent from a mixed composition. The methods may be used to extract or purify specific binding agents from mixed compositions, which compositions comprise other agents capable of binding other antigens. The methods may find particular application as methods for the purification of blood group antigen antibodies.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: May 17, 2022
    Assignee: QBD (QS-IP) LIMITED
    Inventors: Neil Renault, Andrew Gordon Robb, Janine Scott Robb, David Cooper Robson
  • Patent number: 11325961
    Abstract: To provide a therapy and a diagnosis of cancer or an infection using recognition mechanism of a T-cell receptor.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 10, 2022
    Inventor: Koetsu Ogasawara
  • Patent number: 11313860
    Abstract: The capabilities of using gold nanoparticle as surface-enhanced Raman scattering (SERS) substrate to obtain cervical smear harvested cells biochemical information for non-invasive cervical precancerous detection were presented in this patent document. A SERS reagent and a platform has been developed and optimized for the generation of a differential spectral fingerprinting for cervical cancer detection. SERS measurements were performed on three group's cervical exfoliated cell samples: one group from patients (n=36) with pathologically confirmed cervical cancer and another group with high-grade squamous intraepithelial lesion (HSIL) (n=41) and the last group from healthy volunteers (control subjects, n=47).
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 26, 2022
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kaustabh Kumar Maiti, Varsha Karunakaran, Kunjuraman Sujathan
  • Patent number: 11312944
    Abstract: Compositions comprising modified recombinant polymerizing enzymes are provided, along with nucleic acid molecules encoding the modified polymerizing enzymes. In some aspects, methods of using such polymerizing enzymes to synthesize a nucleic acid molecule or to sequence a nucleic acid template are provided.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: April 26, 2022
    Assignee: Quantum-Si Incorporated
    Inventors: Brian Reed, Mohammad Wadud Bhuiya, Manjula Pandey, Jeremy Lackey, Jonathan M. Rothberg, Thomas Christian
  • Patent number: 11299734
    Abstract: The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: April 12, 2022
    Inventors: Neil Aronin, Phillip D. Zamore
  • Patent number: 11293027
    Abstract: The present invention provides a recombinant Bacillus subtilis with improved 2?-fucosyllactose production, and a construction method thereof. In the present invention, a strain capable of efficiently synthesizing 2?-fucosyllactose is obtained by the fusion expression of the fucosyltransferase gene and the L-fucokinase/guanosine 5?-diphosphate-L-fucose pyrophosphorylase gene in Bacillus subtilis BSGL-FF, the fermentation supernatant of which comprises a cumulative amount of 2?-fucosyllactose as high as 1.62 g/L, which is 55% higher than the amount achieved with the control strain. The construction method of the recombinant Bacillus subtilis of the present invention is simple, and convenient to use, and thus has good application prospects.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: April 5, 2022
    Inventors: Long Liu, Jian Chen, Xueqin Lv, Guocheng Du, Jianghua Li, Jieying Deng, Ke Liu
  • Patent number: 11279752
    Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 22, 2022
    Inventors: John C. Williams, Ulrich Rodeck, Kurt Jenkins
  • Patent number: 11274144
    Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: March 15, 2022
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Patent number: 11273206
    Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing bifunctional fusion polymers or nanoparticles. These fusion polymers and nanoparticles contain two or more domains: (i) sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous lesions and (ii) domains that bind to pharmaceutical agents. The drug-binding functionality of these fusion polymers and nanoparticles is based on high-affinity, non-covalent interactions.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 15, 2022
    Assignee: Counterpoint Biomedica LLC
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Patent number: 11267863
    Abstract: Disclosed are a novel N-terminal fusion partner, a fusion polypeptide including the fusion partner and a target polypeptide, and a method for producing a target polypeptide using the same. The novel fusion partner can enhance the yield of a target polypeptide (recombinant polypeptide) compared to the conventional fusion partners. Using the novel fusion partner is particularly beneficial in producing a target polypeptide having a relatively low molecular weight and an easily degradable amino terminus based on genetic recombination technologies. Further, the novel fusion polypeptide including the fusion partner can be expressed as inclusion bodies in a host cell and protected against proteases or the like in a host cell, which makes the target polypeptide produced stably. Therefore, in comparison to the conventional fusion partners, the novel fusion partner can be used to provide a method for producing a recombinant peptide with improved stability and yield.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 8, 2022
    Assignee: PEPGENE INC.
    Inventor: Sung Gun Kim
  • Patent number: 11260098
    Abstract: An appetite-suppressing composition is characterized by comprising, as an active component, the liquid component derived from Indian mulberry (Morinda citrifolia). The solution is the liquid component extracted from fermented Indian mulberry fruits, which includes the residual liquid containing the >3,000 component and the filtrated liquid containing the <3,000 component. Considerably, provided is the food that possesses the appetite-suppressing composition without showing the non-specific effect on appetite suppression.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 1, 2022
    Inventor: Masatomo Mori
  • Patent number: 11254712
    Abstract: Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: February 22, 2022
    Assignee: The University of Queensland
    Inventors: Keith Joseph Chappell, Daniel Watterson, Paul Robert Young
  • Patent number: 11254727
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 11255862
    Abstract: The present invention refers to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals. The present invention further refers to a method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the following steps: i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 22, 2022
    Inventors: Yves Henrotin, Christelle Sanchez, Edwin De Pauw, Gabriel Mazzucchelli
  • Patent number: 11248202
    Abstract: A cell observation device is cell observation device for observing a cell held by a microplate having a well holding a sample including the cell and includes a microplate holder for holding the microplate thereon, an electrical stimulation unit including an electrode pair including a first electrode and a second electrode, and a position controller for controlling a position of the electrical stimulation unit in a state in which the first electrode is disposed closer to the center of the well than the second electrode when the electrode pair is disposed in the well of the microplate. The tip of the first electrode extends more than the tip of the second electrode.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: February 15, 2022
    Inventors: Natsumi Saito, Taira Ito, Takuji Kataoka
  • Patent number: 11242365
    Abstract: The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 8, 2022
    Inventors: Sachiko Yamashita, Tetsuro Hikichi
  • Patent number: 11236145
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 1, 2022
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • Patent number: 11225689
    Abstract: The present invention provides for methods of identifying cell types and cell subtypes from a biological sample or population of target cells. The methods further provide for determining cell type or cell subtype signatures. The method further provides for bipolar cell subtypes and markers and cell signatures thereof.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: January 18, 2022
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Karthik Shekhar, Sylvain Lapan, Irene Whitney, Evan Macosko, Steven McCarroll, Constance Cepko, Aviv Regev, Joshua Sanes
  • Patent number: 11214606
    Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: January 4, 2022
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall J. Mrsny, Tahir Mahmood, Amir Porat, Charles Olson, Sally Postlethwaite, Weijun Feng, Khushdeep Mangat